title: Clinical comparison of the selective serotonin3 antagonists ramosetron and granisetron in treating acute chemotherapy-induced emesis, nausea and anorexia.
abstract: OBJECTIVE
  The efficacies of the selective 5-hydroxytryptamine3 (5-HT3) antagonists--ramosetron (0.3 mg) and granisetron (3 mg) in treating acute chemotherapy-induced digestive system dysunction were compared.
  
  
  METHODS
  A total of 111 patients were enrolled in a single-blind, randomised crossover study; with data from 98 were used to assess efficacy and data from 110 to assess the safety profile. Ramosetron or granisetron was given intraveneously 15 min befire chemotherpy.
  
  
  RESULTS
  The ability of ramosetron to prevent emesis, nausea and anorexia was similar to granisetron during the first 6 h following the administration of chemotherapy, ciplatin or doxorubicin. However, during the first 24 h after chemotherapy, significant differences between ramosetron and granisetron appeared: emetic episode (P = 0.068), nausea (P = 0.006), and anorexia (P = 0.048) remained lower in ramosetron-treated patients. The safety profile of ramosetron was similar to that of granisetron and adverse events in both groups were generally mild and transient.
  
  
  CONCLUSIONS
  Ramosetron is more potent and longer-lasting than granisetron in preventing chemotherapy-induced digestive disturbances.
authors.affiliation: The Cancer Hospital of the CAMS & PUMC, Beijing 100021.
authors.forename: Fengyi
authors.initials: F
authors.lastname: Feng
authors.forename: Pin
authors.initials: P
authors.lastname: Zhang
authors.forename: Youjian
authors.initials: Y
authors.lastname: He
authors.forename: Yuhong
authors.initials: Y
authors.lastname: Li
authors.forename: Meizhen
authors.initials: M
authors.lastname: Zhou
authors.forename: Gang
authors.initials: G
authors.lastname: Chen
authors.forename: Lin
authors.initials: L
authors.lastname: Li
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000855:Anorexia / Q000139:chemically induced / Q000188:drug therapy; D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects; D001562:Benzimidazoles / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects; D018592:Cross-Over Studies; D004317:Doxorubicin / Q000009:adverse effects; D005260:Female; D017829:Granisetron / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D016037:Single-Blind Method; D014840:Vomiting, Anticipatory / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D001562:Benzimidazoles; D002945:Cisplatin; D004317:Doxorubicin; D017829:Granisetron; D012702:Serotonin Antagonists; C071315:ramosetron